The Effects of Moclobemide on Autonomic and Cognitive Functions in Healthy Volunteers

Background: Moclobemide, a reversible and selective inhibitor of the MAO-A isoenzyme, is marketed as an antidepressant that lacks autonomic and cognitive side effects. However, only few and inconclusive quantitative data on the effects of moclobemide on autonomic and cognitive functions have been reported in the literature. Therefore, a double-blind, randomized, placebo-controlled crossover trial was performed. Methods: Twelve healthy male volunteers (age 22-29 years) received orally 150 mg moclobemide b. i. d. and placebo for 14 days each. Heart rate variability (HRV) and skin conductance response (SCR) following sudden deep breath were employed as parameters for autonomic function. Quantitative EEG (qEEG) and psychometric tests served as parameters for cognitive function. Measurements were performed before the start of drug administration and repeatedly on the last treatment day. Results: Parameters of HRV and SCR were not changed by multiple dosing with moclobemide (P > 0.05). Neither cognitive functions such as flicker fusion frequency, memory, choice reaction time, and psychomotor performance nor qEEG was significantly influenced, but subjective tiredness was decreased at all time points of measurement after multiple dosing with moclobemide (P < 0.05). Conclusions: In conclusion, moclobemide does not appear to influence autonomic functions or cognitive functions when given subchronically to healthy humans. In contrast, changes in subjective mood hint at a subtle activating effect.

References

• 1 Anand R, Wesnes K -A. Cognition-enhancing effects of moclobemide, a reversible MAO inhibitor, in humans.  Adv Neurol 199. 1990;  15 261-268
• 2 Coupland N J, Wilson S -J, Potokar J -P, Bell C -E, Bailey J -E, Nutt D -J. A comparison of the effects of phenelzine treatment with moclobemide treatment on cardiovascular reflexes.  Int Clin Psychopharmacol. 1995;  10 229-238
• 3 Da Prada M, Kettler R, Keller H -H, Burkard W -P, Muggli-Maniglio D, Haefely W -E. Neurochemical profile of moclobemide, a short acting and reversible inhibitor of monoamine oxidase type A.  J Pharmacol Exp Ther. 1989;  248 400-414
• 4 Delini-Stula A, Baier D, Kohnen R, Laux G, Phillip M, Scholz H -J. Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A-inhibitor - results of the drug utilization observation studies.  Pharmacopsychiatry. 1999;  32 61-67
• 5 Eschweiler G -W, Bartels M, Langle G, Wild B, Gaertner I, Nickola M. Heart rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine?.  Pharmacopsychiatry. 2002;  35 96-100
• 6 Fairweather D -B, Kerr J -S, Hindmarch I. The effects of moclobemide on psychomotor performance and cognitive function.  Int Clin Psychopharmacol. 1993;  8 43-47
• 7 Finberg J -P-M. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A.  Acta Psychiatr Scand. 1995;  91(Suppl 386) 8-13
• 8 Galderisi S, Mucci A, Bucci P, Mignone M -L, Maj M. Influence of moclobemide on cognitive functions of nine depressed patinets: pilot trial with neurophysiological and neuropsychological indices.  Neuropsychobiology. 1996;  33 48-54
• 9 Gibson S -J. The measurement of mood states in older adults.  J Gerontol Psycholog Sci. 1997;  52B P167-174
• 10 Hasler G, Schnyder U, Klaghofer R, Angst J. Treatment of depressive disorders with and without medication - A naturalistic study.  Pharmacopsychiatry. 2002;  35 235-238
• 11 Hindmarch I, Barwell F, Alford C. Behavioral toxicity of antidepressants. In Leonhard B, Spencer P, editors Antidepressants 30 years on. London; CNS Publishers 1990: 403-409
• 12 Jacobs S -C, Friedman R, Parker J -D, Tofler G -H, Jimenez A -H, Muller J -E, Benson H, Stone P -H. Use of skin conductance changes during mental stress testing as an index of autonomic arousal in cardiovascular research.  Am Heart J. 1994;  128 1170-1177
• 13 Kerr J -S, Fairweather D -B, Hindmarch I. The effects of acute and repeated doses of moclobemide on psychomotor performance and cognitive function in elderly volunteers.  Hum Psychopharmacol. 1992;  7 273-279
• 14 Koulu M, Scheinin M, Kaarttinen A, Kallio J, Pyykko K, Vuorinen J, Zimmer R -H. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.  Br J Clin Pharmacol. 1989;  27 243-255
• 15 Low P -A, Opfer-Gehrking T -L. Differential effects of amitriptyline on sudomotor, cardiovagal, and adrenergic function in human subjects.  Muscle Nerve. 1992;  15 1340-1344
• 16 Low P -A, Opfer-Gehrking T -L, Kihara M. In vivo studies on receptor pharmacology on the human eccrine sweat gland.  Clin Autonom Res. 1992;  2 29-34
• 17 Mackay F -R, Dunn N -R, Martin R -M, Pearce G -L, Freemantle S -N, Mann R -D. Newer antidepressants: a comparison of tolerability in general practice.  Br J Gen Pract. 1999;  49 892-896
• 18 Moll E, Neumann N, Schmid-Burgk W, Stabl M. Safety and efficacy during long-term treatment with moclobemide.  Clin Neuropharmacol. 1994;  17 (suppl 1) S74-87
• 19 Mueck-Weymann M. Methoden und Technik. In Mueck-Weymann M, editor Autonome Funktionskreise in Psychosomatik und Psychiatrie. Nicht-invasives Biomonitoring in der Psychopharmakotherapie. Lage; Hans Jacobs 2000: 28-38
• 20 Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, Barbanoj M -J. Differential effects of a new adrenergic agonist -modafinil- and D-amphetamine on sleep and early morning behaviour in young healthy volunteers.  Int J Clin Pharmacol Res. 1989;  9 183-195
• 21 Saletu B, Gruber G, Saletu M, Brandstatter N, Hauer C, Prause W ,. et al . Sleep laboratory studies in restless legs syndrome as compared with normals and acute effects of ropinirole. 1. findings on objective and subjective sleep and awakening quality.  Neuropsychobiology. 2000;  41 181-189
• 22 Shields R -W. Functional anatomy of the autonomic nervous system.  J Clin Neurophysiol. 1993;  10 2-13
• 23 Siepmann M, Krause S, Joraschky P, Mueck-Weymann M, Kirch W. The effects of St. John`s wort extract on heart variability, cognitive functions and quantitative EEG - a comparison with amitriptyline and placebo in healthy men.  Br J Clin Pharmacol. 2002;  54 277-282
• 24 Siepmann M, Mueck-Weymann M, Joraschky P, Kirch W. The effects of reboxetine on autonomic and cognitive functions in healthy volunteers.  Psychopharmacology. 2001;  157 202-207
• 25 Smirni P, Villardita C, Tappala G. Influence of different paths on spatial memory performance in the block-tapping test.  Clin Neuropsychol. 1983;  5 355-359
• 26 Smith M -D. Rapid method for determination of riboflavin in urine by high-performance liquid chromatography.  J Chromatogr. 1980;  182 285-291
• 27 Spyer K -M. Central nervous system control of the cardiovascular system. In Bannister R, editor Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. Oxford; Oxford University Press 1988: 56-79
• 28 Ueda N, Yoshimura R, Shinkai K, Nakamura J. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression.  Pharmacopsychiatry. 2002;  35 175-181
• 29 Wesnes K, Simpson P, Christma S, Anand R, McClelland G. The effects of moclobemide on cognition.  J Neurol Transm. 1989;  28 91-102
• 30 Wiesel F -A, Raaflaub J, Kettler R. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.  Eur J Clin Pharmacol. 1985;  28 89-95
• 31 Yamadera H, Ferber G, Matejcek M, Pokorny R. Quantitative pharmaco-electroencephalographic differentiation between the CNS effects of bromocriptine and imipramine, drugs with qualitatively different antidepressant properties.  Pharmacopsychiatry. 1987;  20 54-59